Daewoong Pharmaceutical Holds Regular General Meeting of Shareholders... "Achieves Triple Crown"

Three Major New Drugs Nabota, Pexuclu, and Enblo Accelerate Leap to Global Blockbusters
Securing Future Growth Engines through AI, Digital Healthcare, and Talent Development

Lee Chang-jae, CEO of Daewoong Pharmaceutical, is speaking at the 23rd Daewoong Pharmaceutical Annual General Meeting of Shareholders. Photo by Daewoong Pharmaceutical

Daewoong Pharmaceutical held its 23rd regular general meeting of shareholders at its headquarters in Seoul on the 26th, sharing last year's management performance and this year's strategic direction.

At this shareholders' meeting, all three agenda items were approved as originally proposed. Professor Kwon Soon-yong from Seoul St. Mary's Hospital was appointed as a new outside director. In addition, the remuneration limits for directors and auditors were set and approved at the same level as the previous year.

Daewoong Pharmaceutical announced last year's performance, achieving the 'Triple Crown' (simultaneous growth in sales, operating profit, and operating profit margin) with the best results since its founding. Last year, consolidated sales increased by 3.4% year-on-year to KRW 1.4227 trillion, operating profit rose by 20.7% to KRW 147.9 billion, and the operating profit margin reached 10.4%.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “Despite intensified global competition and economic uncertainties, we were able to achieve remarkable results thanks to the continuous interest and support of our shareholders,” adding, “We will continue to maximize corporate value through sustainable growth and raise Daewoong’s name even higher in the global market.”

Three Major New Drugs Nabota, Pexuclu, and Enblo Accelerate Leap to Global Blockbusters

One of the key achievements is the progress of the gastroesophageal reflux disease treatment 'Pexuclu.' Pexuclu, which became a blockbuster with annual sales of KRW 100 billion within three years of its launch, is accelerating its leap to a global blockbuster drug by actively expanding into overseas markets.

The diabetes treatment 'Enblo' is also rapidly growing in the domestic market, expanding its market share, and is currently undergoing approval processes in major countries for global expansion. Both products are accelerating overseas market expansion through collaboration with global pharmaceutical companies.

The botulinum toxin product 'Nabota' has solidified its position as the second-largest aesthetic toxin in the U.S. market and is rapidly increasing its market share in Europe, Latin America, and Asia. Daewoong Pharmaceutical plans to further strengthen its global leadership through customized marketing strategies and enhanced local partnerships.

Securing Future Growth Engines through AI, Digital Healthcare, and Talent Development

Daewoong Pharmaceutical is also accelerating efforts to secure future growth engines. It is developing various digital healthcare technologies, including the AI-based smart bed monitoring solution 'Think,' continuous glucose monitors, wearable electrocardiogram devices, and monitoring devices for vision loss diseases, aiming to become a total healthcare company covering diagnosis, management, and prevention.

Additionally, the company is expanding its innovative drug pipeline, including its own anticancer drug candidates and oral treatments for liver fibrosis, and actively pursuing next-generation formulation technology development through open collaboration.

In terms of talent strategy, Daewoong Pharmaceutical has established a talent management system centered on autonomy, growth, and performance, creating a 'great place to work' and a 'high-performing company' where employees can proactively demonstrate their capabilities regardless of age, tenure, gender, or nationality. This competency-based, high-performing organizational culture enhances global competitiveness.

CEO Lee emphasized, “Daewoong Pharmaceutical will nurture global blockbuster drugs through the 'One Product, One Trillion Won' vision, achieving annual sales of KRW 1 trillion from a single product, and leap onto the global stage beyond Korea. We will realize sustainable growth with global competitiveness that never stops changing and innovating.”

Daewoong Pharmaceutical plans to continue strengthening its corporate foundation through transparent governance, enhanced ESG management, and securing financial soundness, solidifying a long-term growth foundation together with its shareholders.

This content was produced with the assistance of AI translation services.